Biotech / Pharma Reports
Financing breaks all records in 2020
2020 global life sciences outlook
The Pharmaceutical Industry in Figures 2020
JP Morgan – Life Sciences in a Changing World: Startup Outlook Through 2020
Biopharma leaders prioritize R&D, technological transformation, and global market presence
Venture Capital, Private Equity & Hedge Funds
Understanding Venture Capital Term Sheets
Top biotech Venture Capital Funds in 2018, 2019 and 2020
Venture capital found its footing in biotech. Then came the virus.
Swiss Venture Capital Report 2021
Probability-Weighted Expected Return Method
Biotech licensing deals
BioPharmaceutical Royalty Rates & Deal Terms Report
Biotech Valuation and Deal Structuring
R&D Licensing in the Biopharmaceutical Industry: How to Structure a Good Deal
Pharmaceutical and Biotech Deal Structuring
Maximizing Royalty Rate Opportunities in Pharma Licensing
Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb
Determining Pharmaceutical Royalties
Considering Pharmaceutical Royalties
Analyzing Intellectual Property Royalty Rate Data
Milestone payments in biopharma: negotiating an equitable value allocation
Biotech Valuation
Discounted Cash Flow Valuation Basics
Putting a price on Biotechnology
Valuation Analysis in Pharmaceutical Licensing and M&A Transactions
The Cost of Capital for Early-Stage Biotechnology Ventures
Cost of Capital for Pharmaceutical, Biotechnology, and Medical Device Firms
Probabilistic Forecasting of Pharmaceutical Projects and Portfolios
Should we discount by project or by company?
Should we discount by project or by company? (continued)
Application of real options analysis for pharmaceutical R&D project valuation
Regression Analysis in Valuation Engagements
M&A
HBM Pharma/Biotech M&A Report 2020A Decade of
Biopharma M&A and Outlook for 2020
A simple M&A model for all seasons
How will deals done now deliver what the health ecosystem needs next?
Global Healthcare Private Equity and M&A Report 2020
R&D productivity / R&D costs / Clinical success rates
How to improve R&D productivity: the pharmaceutical industry’s grand challenge
Ten years on – Measuring the return from pharmaceutical innovation
The cost of biopharmaceutical R&D: Is biotech different?
Clinical Development Success Rates 2006-2015
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances